Lancet infect dis:皮肤利什曼病的全球负担(2013世界疾病负担研究)

2016-02-13 MedSci MedSci原创

原始出处:Chante Karimkhani,  Valentine Wanga, et al,Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013,lancet,12 February 2016http://www

评估皮肤利什曼病的负担仍缺乏高质量的流行病学研究。我们比较了皮肤利什曼病的从国家到全球的负担,评估国家与地区之间的差异。

数据来源:科学文献,医院资源,国家报告,WHO关于急慢性皮肤利什曼病后遗症的资料。患病率数据与伤残权重产生的伤残生命年结合起来。伤残调整生命年(DALYs)是残疾生存和死亡丢失年数的总和(或死亡,假定为0)。我们使用标准的Z分数分析Bonferroni调整(p.<.0.003)代洛伦茨曲线和基尼系数比较了125个国家的DALYs。

2013年皮肤利什曼病全球平均年龄标准化的.DALYs是0.58/100000人。9个国家DALYs显著大于平均值:阿富汗(87.0)、苏丹(20.2)、叙利亚(9.2),也门(6.2)、伊拉克(6.0),布基纳法索(4.8),玻利维亚(4.6)、海地(4..1)和秘鲁(4.0)。基尼系数是0.89。安第斯拉丁美洲、北非和中东,西方撒哈拉以南非洲和南亚的DALYs最高。在男性中,巴勒斯坦发病率最高(616.2例/100000人),其次是阿富汗(566.4)、叙利亚(357.1),和尼加拉瓜(354.8)。阿富汗女性发病率最高(623.9),叙利亚(406.3),巴勒斯坦(222.1),和尼加拉瓜(180.8)。类似比例的男性和女性在大多数国家的皮肤利什曼病发病率高。

说明:皮肤利什曼病主要的负担落在非洲和中东国家。全球和各国皮肤利什曼病的疾病负担数据是促进研究领域和开始行为改变的关键。

原始出处:


Chante Karimkhani,  Valentine Wanga, et al,Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013,lancet,12 February 2016


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012072, encodeId=c06d20120e293, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 12 08:28:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951232, encodeId=97b0195123292, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Nov 03 05:28:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828401, encodeId=8b9218284015b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 27 04:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64570, encodeId=6ef6645e09e, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Wed Feb 17 16:26:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333580, encodeId=ab6a133358046, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Feb 15 03:28:00 CST 2016, time=2016-02-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012072, encodeId=c06d20120e293, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 12 08:28:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951232, encodeId=97b0195123292, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Nov 03 05:28:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828401, encodeId=8b9218284015b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 27 04:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64570, encodeId=6ef6645e09e, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Wed Feb 17 16:26:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333580, encodeId=ab6a133358046, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Feb 15 03:28:00 CST 2016, time=2016-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012072, encodeId=c06d20120e293, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 12 08:28:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951232, encodeId=97b0195123292, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Nov 03 05:28:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828401, encodeId=8b9218284015b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 27 04:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64570, encodeId=6ef6645e09e, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Wed Feb 17 16:26:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333580, encodeId=ab6a133358046, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Feb 15 03:28:00 CST 2016, time=2016-02-15, status=1, ipAttribution=)]
    2016-03-27 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012072, encodeId=c06d20120e293, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 12 08:28:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951232, encodeId=97b0195123292, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Nov 03 05:28:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828401, encodeId=8b9218284015b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 27 04:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64570, encodeId=6ef6645e09e, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Wed Feb 17 16:26:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333580, encodeId=ab6a133358046, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Feb 15 03:28:00 CST 2016, time=2016-02-15, status=1, ipAttribution=)]
    2016-02-17 1de4ac4em35(暂无匿称)

    不知道

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2012072, encodeId=c06d20120e293, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jul 12 08:28:00 CST 2016, time=2016-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951232, encodeId=97b0195123292, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Nov 03 05:28:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828401, encodeId=8b9218284015b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 27 04:28:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64570, encodeId=6ef6645e09e, content=不知道, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Wed Feb 17 16:26:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333580, encodeId=ab6a133358046, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Feb 15 03:28:00 CST 2016, time=2016-02-15, status=1, ipAttribution=)]

相关资讯

NEJM:巴龙霉素单药或合并庆大霉素治疗皮肤利什曼病效果显著

治疗中典型损伤的反应 医学界迫切需要找到一种简单、有效且其副作用能够被接受的方法来治疗皮肤利什曼病。突尼斯突尼斯市巴斯德研究所Afif Ben Salah博士等人的研究显示,巴龙霉素-庆大霉素联合应用以及巴龙霉素单独用药治疗溃疡性硕大利什曼原虫疾病均安全有效。相关论文近期发表于国际权威杂志NEJM在线版上。研究人员在突尼斯进行了一项随机对照的3期试验,对局部15%巴龙霉素单一使用或与0.5%庆大